Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

504359 Palmitoylethanolamide - CAS 544-31-0 - Calbiochem

Palmitoylethanolamide is an endogenous lipid that acts as a selective agonist for GPR55 receptors. Producing robust anti-inflammatory actions by activating PPARα (EC₅₀ = 3 µM).

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

同义词: N-(2-Hydroxyethyl)hexadecanamide, PEA, Palmidrol

Primary Target: GPR55 receptor
504359
Purchase on Sigma-Aldrich

概述

Replacement Information

重要规格表

CAS #Empirical Formula
544-31-0C₁₈H₃₇NO₂

Products

产品目录编号包装 数量 / 包装
5.04359.0001 玻璃瓶 10 mg
Description
OverviewAn endogenous lipid that acts as a selective agonist for GPR55 receptors (EC50 = 4, 19 800 and > 30 000 nM at GPR55, CB2 and CB1 receptors respectively). Producing robust anti-inflammatory actions by activating PPARα (EC50 = 3 µM).
Catalogue Number504359
Brand Family Calbiochem®
SynonymsN-(2-Hydroxyethyl)hexadecanamide, PEA, Palmidrol
References
ReferencesGriffin, G., et al. 2000. J. Pharmacol. Exp. Ther. 292, 886.
Lambert, D., et al. 2001. Epilepsia. 42, 321.
Lambert, D., et al. 2002. Curr. Med. Chem. 9, 663.
Lo Verme, J., et al. 2005. Life Sci. 77, 1685.
Re, G., et al. 2005. Vet. J. 173, 21.
Ryberg, R., et al. 2007. Br. J. Pharmacol. 152, 1092.
Product Information
CAS number544-31-0
FormWhite solid
Hill FormulaC₁₈H₃₇NO₂
Chemical formulaC₁₈H₃₇NO₂
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetGPR55 receptor
Purity≥99% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
产品目录编号 GTIN
5.04359.0001 04055977263978

Documentation

Palmitoylethanolamide - CAS 544-31-0 - Calbiochem MSDS

职位

物料安全数据表 (MSDS) 

Palmitoylethanolamide - CAS 544-31-0 - Calbiochem 分析证书

标题批号
504359

参考

参考信息概述
Griffin, G., et al. 2000. J. Pharmacol. Exp. Ther. 292, 886.
Lambert, D., et al. 2001. Epilepsia. 42, 321.
Lambert, D., et al. 2002. Curr. Med. Chem. 9, 663.
Lo Verme, J., et al. 2005. Life Sci. 77, 1685.
Re, G., et al. 2005. Vet. J. 173, 21.
Ryberg, R., et al. 2007. Br. J. Pharmacol. 152, 1092.
数据表

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision12-July-2013 JSW
SynonymsN-(2-Hydroxyethyl)hexadecanamide, PEA, Palmidrol
DescriptionAn endogenous lipid that acts as a selective agonist for GPR55 receptors (EC50 = 4, 19 800 and > 30 000 nM at GPR55, CB2 and CB1 receptors respectively). Producing robust anti-inflammatory actions by activating PPARα (EC50 = 3 µM).
FormWhite solid
CAS number544-31-0
Chemical formulaC₁₈H₃₇NO₂
Structure formulaStructure formula
Purity≥99% by HPLC
SolubilityDMSO (20 mM). Slight warming is required for complete solubilization.
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesGriffin, G., et al. 2000. J. Pharmacol. Exp. Ther. 292, 886.
Lambert, D., et al. 2001. Epilepsia. 42, 321.
Lambert, D., et al. 2002. Curr. Med. Chem. 9, 663.
Lo Verme, J., et al. 2005. Life Sci. 77, 1685.
Re, G., et al. 2005. Vet. J. 173, 21.
Ryberg, R., et al. 2007. Br. J. Pharmacol. 152, 1092.